Link To “JAN 2023 | 1 HHS Therapeutics Team Side-by-Side Overview of Therapeutics Authorized or Approved for the Prevention of COVID-19 Infection or Treatment of Mild to Moderate COVID-19” From The HHS Therapeutics Team

In this post, I link to the printable 7-page PDF JAN 2023 | 1 HHS Therapeutics Team Side-by-Side Overview of Therapeutics Authorized or Approved for the Prevention of COVID-19 Infection or Treatment of Mild to Moderate COVID-19 From The HHS Therapeutics Team.

All that follows is from the above resource.

This table is a quick reference summarizing key information for available pre-exposure prophylaxis (PrEP) for preventing COVID-19 infection and for all outpatient therapies currently authorized or approved in the United States for treatment of mild to moderate COVID-19. If Paxlovid and Veklury (remdesivir) are not available, feasible or clinically appropriate, consider Lagevrio.1 COVID-19 Convalescent plasma is an additional authorized therapy for specific immunocompromised patients. This resource will be regularly reviewed and updated.
For full details, please review the Fact Sheets for Healthcare Providers for each product [links in the printable 7-page PDF above-I have included the charts in this post as JPEGS].

Page 1

Page 2

Page 3a

Page 3b

Page 4

Page 5

Page 6

Page 7

 

 

This entry was posted in COVID-19 Treatment. Bookmark the permalink.